Enriched GO terms included processes such as “Phosphorylation” (e.g., SMG1, GSK3A, DYRK2), “Peptidyl-Serine Phosphorylation” (e.g., TNKS, ROCK2), and “Peptidyl-Threonine Phosphorylation” (e.g., LMTK2, CDC42BPB) (Fig. 3G), highlighting molecular mechanisms that may contribute to the higher NFT burden in AD compared to PART (85). The gene discussed is DYRK2; the disease is Alzheimer disease.